SEC Filings
Zenas BioPharma’s Quarterly Loss Reaches $108.9 Million As It Prepares For Potential Drug Launch
Higher trial costs and licensing milestones increased spending, while its funding outlook depends partly on FDA approval.
ZBIO
Zenas BioPharma (ZBIO) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
BlackRock Reports 5% Stake In Zenas BioPharma, 3.29 Million Shares
The asset manager's passive ownership filing counts the shares as of September 30, with sole voting power over 3,226,537 of them.
SEC Filings
Zenas Puts Obexelimab's 12-Month Flare-Free Probability At 0.93 Or 0.87, Depending On Who Counts
Open-label extension data in IgG4-related disease also cover steroid toxicity and a small vaccine sub-study; lupus results are expected next.